As Henri Termeer, chief executive of Genzyme, a big biotechnology firm, argues, “the blockbuster model becomes less important over time as specialised therapies take off.”
就像大型生物技术公司健赞的首席执行官亨利·特米尔(HenriTermeer)所说，“随着时间的推移，个人化药物的推出，依靠拳头产品的商业模式变得越来越不重要了。”
Thepharmaceutical giant Genzyme has started a clinical trial to see whether a drugto treat macular generation could be delivered via long-lasting gene therapyrather than monthly injections.
这种新手段便是基因疗法。 制药业巨头Genzyme已开始一项临床测试，用以确定一种黄斑变性治疗药物是否可以通过疗效持续时间较长的基因疗法而不是每月注射的方式给药。
The pharmaceutical giant Genzyme has started a clinical trial to see whether a drug to treat macular generation could be delivered via long-lasting gene therapy rather than monthly injections.
这种新手段便是基因疗法。制药业巨头Genzyme已开始一项临床测试，用以确定一种黄斑变性治疗药物是否可以通过疗效持续时间较长的基因疗法而不是每月注射的方式给药。
Genzyme is a biotechnology company that produces enzymes for treating rare diseases.
Genzyme是一家生物技术公司，它生产的酶用于治疗罕见疾病。
Genzyme is a biotechnology company that produces enzymes for treating rare diseases.
Genzyme是一家生物技术公司，它生产的酶用于治疗罕见疾病。
应用推荐